Literature DB >> 27188357

[A sero-epidemiological study of hepatitis B among general population in Beijing].

P Gao1, H Wang1, W X Chen1, Y N Sun1, W Zhang1, X H Pang2, X He2, J Wu1.   

Abstract

OBJECTIVE: To understand the sero-prevalence of hepatitis B in general population in Beijing and provide evidence for the prevention and control of hepatitis B.
METHODS: A serological survey was conducted in general population aged >1 year selected through multistage randomized cluster sampling in Beijing from August 2013 to February 2014. The estimated sample size was 5 200. Venous blood samples were collected from them to detect five hepatitis B serological indicators. The information about the hepatitis B immunization history and risk factors of the study subjects were collected through a questionnaire survey.
RESULTS: A total of 6 705 people were surveyed. The sero-positive rates of HBsAg, anti-HBs, anti-HBc and total HBV infection rate were 2.74%, 44.72%, 26.91% and 26.95% respectively. The age standardized rates were 2.73%, 44.83%, 26.84% and 26.87% respectively. As for the general population, in Beijing since the prevalence rate of hepatitis B surface antigen has decreased to 2.73%, <1% in children aged less than 5 years old, <1% in people aged less than 25 years old.
CONCLUSION: The integrated prevention and control strategy of hepatitis B had a significant effect in Beijing. We should continue to strengthen the work of adult hepatitis B vaccination.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27188357     DOI: 10.3760/cma.j.issn.0254-6450.2016.05.014

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  7 in total

1.  Sero-epidemiology study of hepatitis B virus surface antibodies from 2017 to 2019 among Chinese young adults in Hunan Province: A three-year retrospective study.

Authors:  Ming Xie; Hongjiao Quan; Yuan Zeng; Shuqian Yuan; Yinyue Liu; Yide Yang
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

Review 2.  Adult Hepatitis B Virus Vaccination Coverage in China from 2011 to 2021: A Systematic Review.

Authors:  Xinxin Bai; Lu Chen; Xinyao Liu; Yujia Tong; Lu Wang; Minru Zhou; Yanming Li; Guangyu Hu
Journal:  Vaccines (Basel)       Date:  2022-06-06

3.  External validation of non-invasive prediction models for identifying ultrasonography-diagnosed fatty liver disease in a Chinese population.

Authors:  Ya-Nan Shen; Ming-Xing Yu; Qian Gao; Yan-Yan Li; Jian-Jun Huang; Chen-Ming Sun; Nan Qiao; Hai-Xia Zhang; Hui Wang; Qing Lu; Tong Wang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

4.  Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study.

Authors:  Shigui Yang; Cheng Ding; Yuanxia Cui; Jie Wu; Chengbo Yu; Ping Chen; Kaijin Xu; Min Deng; Yiping Li; Juanjuan Liu; Pei Yin; Wen Ren; Yan Qiu; Qing Cao; Yuqing Zhou; Jun Yao; Bing Ruan; Jingjing Ren; Lanjuan Li
Journal:  BMJ Open       Date:  2017-04-03       Impact factor: 2.692

5.  Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China.

Authors:  Min Li; Lianhui Zhao; Jialing Zhou; Yameng Sun; Xiaoning Wu; Xiaojuan Ou; Hong You; Yuanyuan Kong; Jidong Jia
Journal:  Lancet Reg Health West Pac       Date:  2021-08-25

6.  Cancer incidence in Beijing, 2014.

Authors:  Shuo Liu; Lei Yang; Yannan Yuan; Huichao Li; Jing Tian; Sijia Lu; Ning Wang; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

7.  Cost-utility analysis of newborn hepatitis B immunization in Beijing.

Authors:  Yiwei Guo; Yong Yang; Qian Bai; Zhengwei Huang; Zongwu Wang; Dongxia Cai; Shuo Li; Xiaowei Man; Xuefeng Shi
Journal:  Hum Vaccin Immunother       Date:  2020-10-05       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.